Q4 2024 Collegium Pharmaceutical Inc Earnings Call Transcript
Key Points
- Collegium Pharmaceutical Inc (COLL) reported a record net product revenue of $181.9 million for the fourth quarter, up 22% year over year.
- The acquisition of Ironshore Therapeutics and its lead medicine, Jornay APM, has been successful, with prescriptions growing 29% year over year and 11% quarter over quarter.
- The company achieved its financial guidance for 2024, growing total revenue by 11% and adjusted EBITDA by 9% year over year.
- Collegium Pharmaceutical Inc (COLL) strengthened the durability of the Nucynta franchise with several positive developments, extending projected exclusivity to July 2027.
- The company has a strong financial position, ending 2024 with net leverage of less than two times and expecting to end 2025 with net leverage of less than one time.
- GAAP operating expenses increased significantly, up 83% year over year for the fourth quarter and 30% for the full year 2024.
- The Nucynta franchise saw a decline in net revenue, down 11% year over year for the fourth quarter and 7% for the full year 2024.
- There is expected pressure on prescriptions in the first quarter of 2025 due to a formulary change and typical first-quarter dynamics driven by patient deductible resets.
- The company faces risks and uncertainties related to the commercialization of its products and potential litigation.
- GAAP net income for the fourth quarter decreased to $12.5 million compared to $31.9 million in the fourth quarter of 2023.
Greetings and welcome to the Collegium Pharmaceuticals, fourth quarter in full year 2024 earnings conference call.
(Operator Instructions)
Please note that this conference call is being recorded. I'll now give a call over to Danielle Jesse, the director of Investor Relations at Collegium.
Thank you and you may begin.
Welcome to Collegium Pharmaceuticals fourth quarter and full year 2024 earnings conference call. I am joined today by Vikram Karnani, our President and Chief Executive Officer, Colleen Tupper, our Chief Financial Officer, and Scott Dyer, our Chief Commercial Officer.
Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional and that any forward-looking statements made today are made pursuant to the safe harbour provision of the Private Securities Litigation Reform Act of 1,995.
You are cautioned that such forward-looking statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
